Clinical Issues in Bipolar Depression: Consensus and Controversies Across the Spectrum of Patient Presentations

Clinical Issues in Bipolar Depression: Consensus and Controversies Across the Spectrum of Patient Presentations

On-Demand Webcast
FACULTY

Catherine Judd, MS, PA-C, CAQ-Psy, DFAAPA
Clinical Assistant Professor
UT Southwestern Medical Center
Dallas, Texas
Senior, Physician Assistant, Mental Health Services
Parkland Health and Hospital System
Dallas, Texas

Roger S. McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology, University of Toronto
Executive Director, Brain and Cognition Discovery Foundation (BCDF)
Head, Mood Disorders Psychopharmacology Unit
University Health Network
Toronto, Ontario, Canada

Gary S, Sachs, MD
Associate Clinical Professor of Psychiatry
Harvard Medical School
Founding Director, Bipolar Clinic and Research Program
Massachusetts General Hospital
Boston, Massachusetts 

For full faculty bios, please call 609-371-1137.

INTENDED LEARNERS

This activity is intended for psychiatrists, primary care physicians, psychologists, physician assistants, psychiatric nurses, and other healthcare professionals who seek to improve the care of patients with mental health disorders.

LEARNING OBJECTIVES

After completing this activity, participants should be able to:

  • Accurately diagnose bipolar depression, including episodes that meet the criteria for the mixed features specifier in the DSM-5, based on comprehensive patient evaluations and collateral histories
  • Discuss the clinical profiles of and long-term management considerations for medications that are available to treat bipolar depression
  • Tailor therapeutic regimens for major depressive episodes experienced by patents with bipolar disorder or by those at increased risk for emergent hypomania/mania
  • Communicate with patients with bipolar depression to provide disease state education, encourage shared decision-making, and improve treatment adherence
ACTIVITY OVERVIEW

To be eligible for documentation of credit, participants must participate in the full activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: 3/31/2017
Expiration Date: 3/31/2018
Estimated time to complete: 1.0 hour

For questions regarding this educational activity, please call 609-371-1137.

There is no fee associated with this activity.

ACCREDITATION INFORMATION

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Integritas Communications. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME

NACCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE

This continuing nursing education activity awards 1.0 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hour.

PHARMACOLOGY CREDITS

This continuing nursing educational activity awards up to 0.5 pharmacology hours.

CE INFORMATION

APA
North American Center for Continuing Medical Education, LLC (NACCME) is approved by the American Psychological Association to sponsor continuing education for psychologists. NACCME maintains responsibility for this program and its content.

Instructional Level: Advanced

PLANNING COMMITTEE

The planning committee comprises of Catherine Judd, MS, PA-C, CAQ-Psy, DFAAPA; Roger S. McIntyre, MD, FRCPC, Gary S, Sachs, MD; Douglas L. Noordsy, MD; Andrew Penn, RN, MS, NP, CNS, APRN-BC; Jim Kappler, PhD, Rose O’Connor, PhD, Integritas Communications; Raquel Gaerlan, Mike Kearney, Meaghan O’Brien, Randy Robbin, and John Savage, NACCME.

Independent Clinical Reviewer: Douglas L. Noordsy, MD, Clinical Professor of Psychiatry & Behavioral Sciences, Stanford University School of Medicine; Director of Sports Psychiatry, Department of Psychiatry & Behavioral Sciences, Stanford University, Stanford, California

Nurse Planner: Andrew Penn, RN, MS, NP, CNS, APRN-BC, Psychiatric Nurse Practitioner, Kaiser Permanente, Redwood City, CA; Assistant Clinical Professor, University of California, San Francisco, CA

FINANCIAL DISCLOSURE AND CONFLICTS OF INTEREST

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. McIntyre: Advisory Board—Astra Zeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, Janssen-Ortho, Eli Lilly, Organon, Lundbeck, Pfizer, Shire, Merck; Speakers Bureau—Janssen-Ortho, Astra-Zeneca, Eli Lilly, Merck, Pfizer; CME Activities—Astra Zeneca, Bristol-Myers Squibb, France Foundation, I3CME, Physicians’ Postgraduate Press, CME Outfitters, Optum Health, Merck, Eli Lilly, Pfizer; Research Support—Eli Lilly, Janssen-Ortho, Shire, Astra-Zeneca, Pfizer, Lundbeck

Dr. Sachs: Advisory Board—Allergan, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda

Ms. Judd, Mr. Penn, and Dr. Noordsy have disclosed no relevant financial relationships with any commercial interests.

Ms. Gaerlan, Mr. Kearney, Ms. O’Brien, Mr. Robbin, Mr. Savage; Mr. Kappler and Mrs. O’Connor disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

Off-label/unapproved uses of drugs and/or devices will be disclosed prior to the start of the symposium.

HARDWARE/SOFTWARE REQUIREMENTS

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

PRIVACY POLICY

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2017 by North American Center for Continuing Medical Education, LLC (NACCME). All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from NACCME. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

GRANT SUPPORT

Supported by an educational grant from Sunovion Pharmaceuticals Inc.